Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The majority of endometrial cancer patients with disease spread beyond the uterus will
progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in
metastatic or advanced endometrial cancer. There is no standard protocol for the second-line
option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an
approved drug for the treatment of ALK-positive non-small cell lung cancer, demonstrated
activities in endometrial cancer with c-MET kinase and Sema domain mutations. As a
consequence, a phase 2 clinical trial to investigate the efficacy of Crizotinib in
endometrial cancer patients with MET mutation is initiated.
Phase:
Phase 2
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborators:
Chi Mei Medical Hospital Kaohsiung Medical University Kaohsiung Veterans General Hospital.